Infectious Agents and Cancer
|
Viewing options:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
 Oral presentationGood outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximabK Dunleavy, RF Little, AS Wayne, N Grant, S Pittaluga, ES Jaffe, S Steinberg, R Yarchoan, J Carrasquillo, J Janik and WH Wilson Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA  corresponding author email
from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Bethesda, MD, USA. 6–7 October 2008 Infectious Agents and Cancer 2009,
4(Suppl 2):O9doi:10.1186/1750-9378-4-S2-O9 First paragraph (this article has no abstract)
The addition of rituximab to CHOP chemotherapy may augment tumor response but in patients with low CD4 counts, one study suggested that this benefit may be offset by increased infectious deaths (Kaplan. Blood 2005; 106:1538). We hypothesized that the addition of rituximab to EPOCH chemotherapy could improve tumor kill, allowing fewer cycles of treatment and therefore reducing toxicity. | 
on Google Scholar
